

RESEARCHSPACE@AUCKLAND

http://researchspace.auckland.ac.nz

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage. http://researchspace.auckland.ac.nz/feedback

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

ECONOMIC INCENTIVES AND CLINICAL DECISIONS

Rhema Vaithianathan

A thesis submitted

in partial fulfilment of the requirements

for the degree of Doctor of Philosophy.

The University of Auckland

1999

then a

-- H. R 2000

Acknowledgements

I would like to thank Dr John Small, for his helpful and enthusiastic supervision.

I am grateful to the many people whose helpful insights and comments on earlier drafts have greatly improved the quality of this thesis, particularly Dr Toni Ashton, Dr John Boyce, Nicola Bush, Dr Paul Calcott, Doug James, Professor Stephen King, Dr William Rainger and Dr Alan Rogers. I am also grateful to participants at the 1997 PhD Conference in Economics and Business, Perth, Australia; the 1998 NZAE Conference, Wellington; the LEANZ seminar series; and the Economics Department Graduate Workshop, University of Auckland.

Funding from the Health Research Council is gratefully acknowledged.

The good humour and support of my office-mates, Chris and Doug, made the process of writing this thesis seem far less arduous than it could have been - for which I am thankful.

I would like to thank my parents and my sister for their encouragement and support throughout my years at University.

Finally, I would like to thank my husband, Matthew Ryan, whose wisdom and love have supported me through the course of writing this thesis. He also provided me with detailed comments on earlier drafts of this thesis.

Abstract

In the face of escalating health care expenditure, OECD countries are turning to a variety of cost-containment strategies. This thesis analyses three such mechanisms.

In Part I, I consider the use of coinsurance to limit the demand for health care. Because coinsurance reduces the elasticity of demand with respect to the price of health care, consumers facing low coinsurance rates may be charged a higher price by doctors. Such discriminatory pricing enables the doctor to extract surplus created in the insurance market, and therefore reduces the effectiveness of coinsurance. I show that in equilibrium, some consumers remain uninsured. I also show how this problem is solved if the doctor and insurer enter into managed care style arrangements. Such arrangements improve insurer and doctor profitability, and restore complete insurance market coverage.

In Part II, I consider the design of fundholding schemes which encourage doctors to restrict expensive treatment to severely ill patients. I show that such schemes may be undermined by a patient-doctor side contract. In the face of such patient-doctor collusion, the fundholding scheme may be made collusion-proof by increasing its "power". I show that the optimal collusion-proof scheme may pay the doctor more than his reservation wage. An alternative solution to patient-doctor collusion is to use a partial fundholding scheme that requires some additional co-payment from the patient.

Part III analyses New Zealand's internal market reforms. Introduced in 1993, the reforms involved the separation of funding and provision of health care, and were intended to simulate a competitive market environment, thereby improving the incentives of government owned health care providers to be efficient. On the supply side, I look at the internal restructuring of hospitals into private-sector clones. I argue that this commercialisation failed to take account of informational issues within the hospital. On the demand-side, I examine the suitability of internal markets for eliciting optimal innovation from the hospital sector. Again, I find that a standard argument, namely that increased competition leads to innovation, is questionable in the context of the internal market.

Contents

In	Introduction		
Ι	Ins	surance and Managed Care	25
1	Hea	dth insurance and price discrimination	26
	1.1	Introduction	26
	1.2	Related theoretical literature	31
	1.3	Doctor price discrimination	32
	1.4	A diagrammatic illustration	35
	1.5	The model	39
	1.6	Equilibrium in the insurance market	44
	1.7	Conclusion	54
2	Inte	egration of insurance and provision	57
	2.1	Introduction	57

	2.2	Common ownership	63
	2.3	Preferred provider organisations	67
	2.4	Discussion	69
II	C	ommon Agency and Doctor Reimbursement	73
3	Mon	ral hazard and fundholding	75
	3.1	Introduction	75
	3.2	The model	81
	3.3	The single-principal optimal scheme	84
	3.4	The second-best scheme	90
	3.5	Conclusion	96
4	Pati	ient-doctor collusion	99
	4.1	Introduction	99
	4.2	Related literature	101
	4.3	The model	104
	4.4	Side-payment robust schemes	107
	4.5	Discussion	117
5	Allo	owing side-payments	121

	5.1	Side-p	ayment supplemented scheme	. 121
	5.2	Conclu	usion	. 128
Π	I I	Intern	nal Market Reform in New Zealand	130
6	Intr	oducti	ion to the hospital sector	132
	6.1	Backg	round	. 132
		6.1.1	Administration of the public health expenditure	. 134
	6.2	The fu	anding of hospital services	. 135
		6.2.1	Regional Health Authorities	. 137
		6.2.2	Accident Compensation Corporation	. 142
		6.2.3	Other sources of hospital revenue	. 143
	6.3	Crown	Health Enterprises	. 144
7	Sup	ply-sic	de reform: corporatisation of hospitals	148
	7.1	Introd	luction	. 148
		7.1.1	Changes to the internal organisation of the hospital	. 149
		7.1.2	Principal-Agent theory and the reformed hospital structur	e 152
		7.1.3	The failure of the reforms	. 156
		714	The dismantling of the hospital structures	158

	7.2	The "tw	vo firm" view of the hospital	59
	7.3	Contrac	ting between managers and doctors	62
		7.3.1	Optimal contracts	63
		7.3.2 I	Incomplete contracts	68
		7.3.3 I	Real and formal authority	70
	7.4	Elective	surgery and the private sector	76
	7.5	Policy I	mplications	79
	7.6	Conclus	ion	80
8	Der	nand-sid	le reform: Competition amongst hospitals 18	32
	8.1		ction	82
		Introduc		
		Introduce 8.1.1	ction	84
		8.1.1 7.8.1.2 (ction	84 86
	8.1	8.1.1 7 8.1.2 6 8.1.3 I	Competition in the internal markets	84 86 89
	8.1	8.1.1 7 8.1.2 0 8.1.3 I	Competition in the internal markets	84 86 89
	8.1	Introduction 8.1.1 7. 8.1.2 (8.1.3 Introduction Procure Yardstice Procure Yardstice Procure Pr	The dynamic gains hypothesis	84 86 89 91
	8.1 8.2 8.3	8.1.1 7 8.1.2 6 8.1.3 I Procure Yardstid 8.3.1 7	Ction	84 86 89 91 98

8.5	Competition and ownership	211					
8.6	Conclusion	213					
Conclusion							
Biblio	ography 2	219					
Anne	ndiy 2	239					

List of Figures

1.1	Demand for health care with and without coinsurance	36
1.2	Price discrimination	37
1.3	Price discrimination for small c	38
1.4	Insurer's iso-profit curve	48
1.5	Profitable insurance contracts	52
2.1	Market share of US employer-sponsored insurance plans	59
2.2	US employer-sponsored insurance plan prices	60
3.1	The single principal optimal scheme	88
3.2	Schemes which implement (t_l, t_l)	91
4.1	Timing of events	105
4.2	Doctor-patient subgame: SPRS	109
4.3	Side-payment robust schemes	111

4.4	SPRS which exceeds doctor's reservation utility	٠	٠	*	×	*	*				٠	112
4.5	SPRS which are not optimal	,					į.		×	×	•	115
5.1	Doctor-patient subgame: SPSS	,	×	×	,	÷	×	,				122
5.2	Patient side-payments		¥	*								123
5.3	Side-payment supplemented schemes	,		×	*	ř	ě	٠	ŗ			125
6.1	Funding sources of health care				×	,						133
6.2	Hospital funding				×	×	*	×	×		*	136
6.3	Accountability in the health sector											139

List of Tables

3.1	Cost-effectiveness of ACE Inhibitors (Source: Bonita and Beagle-	
	hole (1998))	8
6.1	Health expenditure by categories	4
6.2	Funding by RHA	8
6.3	Contracted and actual volumes delivered by CHEs (1996/97) 14	6